IVF INVO Fertility, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1417926 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.2%
TTM net income YoY82.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-72.2%
Net margin-59.9%
FCF margin—
EBITDA margin-64.6%
Returns
ROE-40.5%
ROA-21.6%
ROIC (approx.)-34.7%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets29.4%
Debt / equity0.05x
Current ratio1.00x
Interest coverage-5.06x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.22M | $2.18M | $2.02M | $1.58M | $1.76M | $1.86M | $1.64M | $1.69M |
| Cost of revenue | — | $60,147 | $5,152 | — | — | $3,063 | $3,984 | $1.02M |
| Gross profit | — | $2.12M | $2.01M | — | — | $1.86M | $1.63M | $669,068 |
| R&D expense | — | — | — | — | — | — | $265,663 | $484,780 |
| SG&A expense | $2.07M | $1.91M | $2.18M | $1.81M | $2.13M | $2.19M | $1.56M | $3.48M |
| Operating income | -$1.48M | -$1.29M | -$1.59M | -$1.41M | -$1.64M | -$2.99M | -$1.20M | -$1.97M |
| Interest expense | $154,768 | $177,227 | $180,323 | $627,107 | $322,765 | $440,596 | $307,839 | $231,824 |
| Pretax income | -$2.12M | $944,894 | — | $1.86M | -$3.40M | -$1.54M | -$17.40M | -$3.68M |
| Income tax | $29,530 | $56,154 | $0 | — | — | — | $0 | -$54,008 |
| Net income | -$2.15M | $888,740 | -$5.54M | $2.01M | -$3.40M | -$3.62M | -$17.40M | -$3.62M |
| EBITDA | -$1.30M | -$1.14M | -$1.45M | -$1.28M | -$1.50M | -$2.82M | -$965,066 | -$1.73M |
| EPS (basic) | -2.44 | 0.42 | -3.38 | — | -157.43 | -364.23 | -3,473.93 | — |
| EPS (diluted) | -2.44 | 0.35 | -3.38 | — | -157.43 | -364.23 | -3,473.93 | — |
| Weighted avg. shares (diluted) | 880,233 | 2.59M | 1.64M | — | 21,569 | 9,936 | 5,010 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $3.73M | $4.90M | $0 | $355,891 | $549,181 | $840,407 | $619,520 |
| Receivables | $170,423 | $257,729 | $248,387 | $217,263 | $274,200 | $242,255 | $173,614 | $113,108 |
| Inventory | $230,806 | $251,290 | $224,555 | $225,253 | $191,762 | $212,611 | $216,458 | $219,764 |
| Current assets | $4.44M | $4.60M | $5.73M | $2.76M | $1.14M | $1.40M | $1.57M | $1.26M |
| PP&E, net | $814,175 | $832,851 | $474,641 | $386,165 | $405,417 | $428,746 | $451,247 | $466,684 |
| Goodwill | $9.24M | $9.25M | $6.52M | $5.88M | $5.88M | $5.88M | $8.89M | $5.88M |
| Intangibles | $1.25M | $1.36M | $1.37M | $1.33M | $1.43M | $1.54M | $17.90M | $3.28M |
| Total assets | $25.50M | $25.83M | $24.66M | $20.22M | $18.83M | $19.32M | $31.74M | $46.08M |
| Current liabilities | $4.46M | $6.52M | $6.36M | $10.33M | $9.13M | $12.14M | $18.72M | $17.87M |
| Short-term debt | $594,990 | $1.13M | $1.24M | $1.27M | $1.03M | $3.77M | — | $6.34M |
| Long-term debt | $362,445 | $513,386 | $660,165 | $744,725 | $951,668 | $1.04M | — | $1.13M |
| Total debt | $957,435 | $1.64M | $1.90M | $2.02M | $1.98M | $4.81M | — | $7.47M |
| Total liabilities | $7.49M | $9.34M | $9.63M | $13.00M | $13.01M | $16.19M | $24.43M | $26.04M |
| Shareholders' equity | $18.01M | $16.49M | $15.02M | $7.22M | $5.65M | -$7.15M | -$27.20M | $12.58M |
| Net debt | $957,435 | -$2.09M | -$3.00M | $2.02M | $1.63M | $4.26M | — | $6.85M |
| Shares outstanding | 1.19M | 2.30M | 1.64M | 119,358 | 5.42M | 828,110 | 746,227 | 3,111 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.72M | -$1.10M | -$1.92M | $25,207 | -$1.78M | -$1.72M | -$3.55M | -$617,379 |
| Capital expenditure | $44,787 | — | — | $11,823 | $8,062 | $8,877 | $14,650 | $78,874 |
| Free cash flow | -$1.76M | — | — | $13,384 | -$1.78M | -$1.73M | -$3.56M | -$696,253 |
| Investing cash flow | -$44,787 | -$2,216 | -$210,000 | -$2.71M | -$8,062 | -$15,446 | -$14,650 | $393,134 |
| Financing cash flow | $1.72M | -$67,847 | $4.95M | $4.40M | $1.59M | $1.44M | $3.66M | $494,050 |
| Depreciation & amortization | $177,564 | $145,573 | $142,698 | $136,425 | $136,741 | $169,737 | $234,462 | $231,810 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.